.png)
ACRP-CP Practice Questions
ACRP Certified Professional Exam
Last Update 1 day ago
Total Questions : 125
Dive into our fully updated and stable ACRP-CP practice test platform, featuring all the latest ACRP Certified Professional exam questions added this week. Our preparation tool is more than just a ACRP study aid; it's a strategic advantage.
Our free ACRP Certified Professional practice questions crafted to reflect the domains and difficulty of the actual exam. The detailed rationales explain the 'why' behind each answer, reinforcing key concepts about ACRP-CP. Use this test to pinpoint which areas you need to focus your study on.
In a quality management system, in which category do risk reduction activities belong?
During a multi-center, double-blind, placebo-controlled Phase III clinical trial evaluating a novel oncology drug, the following situation occurs:
An interim analysis performed by the DSMB reveals that the investigational product (IP) shows a statistically significant improvement in progression-free survival (PFS) compared to the placebo. However, a sub-group analysis indicates a higher incidence of Grade 4 hepatotoxicity in patients with pre-existing mild liver dysfunction.
The sponsor, upon reviewing the DSMB report, decides to unblind the affected sub-group to assess safety. The trial protocol specifies that unblinding should only occur if a life-threatening situation is identified.
What is the most appropriate next step the sponsor should take?
Per the protocol, participants' blood creatinine level must be no greater than 2.5 times the upper limit of normal (0.7-1.2 mg/dL). What is the maximum creatinine level the participant can have and be eligible for the trial?
Who ensures information regarding payments to subjects is documented in a written consent form?
A PI is being considered for an industry-sponsored study. The PI sees approximately 20 patients per month who meet the study criteria. The PI does not have access to a Positron Emission Tomography (PET) scanner, which is required for the protocol. The PI is already taking part in three other studies. Should the Sponsor choose this PI?
One key attribute for good study documentation is that the data are contemporaneous, which refers to the practice of:
